Hypoxia inducible factor stabilization improves defective ischemia-induced angiogenesis in a rodent model of chronic kidney disease

Kidney International

Volumn 91, Issue 3, 2017, Pages 616-627

  Schellinger, Isabel N ^a,b,c,d,e   Cordasic, Nada ^a   Panesar, Julian ^a   Buchholz, Björn ^a   Jacobi, Johannes ^a   Hartner, Andrea ^a   Klanke, Bernd ^a   Jakubiczka Smorag, Joanna ^d   Burzlaff, Nicolai ^a   Heinze, Eva ^a   Warnecke, Christina ^a   Raaz, Uwe ^d,e   Willam, Carsten ^a   Tsao, Philip S ^b,c   Eckardt, Kai Uwe ^a   Amann, Kerstin ^a   Hilgers, Karl F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

cardiovascular disease; chronic kidney disease; hypoxia

Indexed keywords

CD31 ANTIGEN; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; 2-(1-CHLORO-4-HYDROXYISOQUINOLINE-3-CARBOXAMIDO)ACETIC ACID; CARBON MONOXIDE; FLT1 PROTEIN, RAT; GLYCINE; HEME OXYGENASE; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, RAT; HMOX1 PROTEIN, RAT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOQUINOLINE DERIVATIVE; KDR PROTEIN, RAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE MODEL; GENE EXPRESSION; GENE TARGETING; HINDLIMB; HO 1 GENE; HYDROXYLATION; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; LIMB ISCHEMIA; MALE; MUSCLE ISCHEMIA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RAT; RODENT; SHAM PROCEDURE; SKELETAL MUSCLE; VEGF GENE; VEGF R1 GENE; VEGF R2 GENE; ANALOGS AND DERIVATIVES; ANIMAL; CAPILLARY; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ISCHEMIA; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; CAPILLARIES; CARBON MONOXIDE; CELL LINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLYCINE; HEME OXYGENASE (DECYCLIZING); HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISCHEMIA; ISOQUINOLINES; MALE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN STABILITY; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 85008319247     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.09.028     Document Type: Article

References (63)

1. 1 Coresh, J., Selvin, E., Stevens, L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007), 2038–2047.
2. 2 Nagata, M., Ninomiya, T., Doi, Y., et al. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study. Nephrol Dial Transplant 25 (2010), 2557–2564.
3. 3 Eckardt, K.U., Coresh, J., Devuyst, O., et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382 (2013), 158–169.
4. 4 Di Angelantonio, E., Chowdhury, R., Sarwar, N., et al. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ, 341, 2010, c4986.
5. 5 Wattanakit, K., Folsom, A.R., Selvin, E., et al. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Amer Soc Nephrol 18 (2007), 629–636.
6. 6 Semenza, G.L., Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem 102 (2007), 840–847.
7. 7 Choi, J.H., Kim, K.L., Huh, W., et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24 (2004), 1246–1252.
8. 8 Di Marco, G.S., Reuter, S., Hillebrand, U., et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Amer Soc Nephrol 20 (2009), 2235–2245.
9. 9 Maxwell, P.H., Ratcliffe, P.J., Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13 (2002), 29–37.
10. 10 Lee, P.J., Jiang, B.H., Chin, B.Y., et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272 (1997), 5375–5381.
11. 11 Tuder, R.M., Flook, B.E., Voelkel, N.F., Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95 (1995), 1798–1807.
12. 12 Dulak, J., Loboda, A., Zagorska, A., et al. Complex role of heme oxygenase-1 in angiogenesis. Antioxid Redox Signal 6 (2004), 858–866.
13. 13 Flisinski, M., Brymora, A., Bartlomiejczyk, I., et al. Decreased hypoxia-inducible factor-1alpha in gastrocnemius muscle in rats with chronic kidney disease. Kidney Blood Press Res 35 (2012), 608–618.
14. 14 Chiang, C.K., Tanaka, T., Inagi, R., et al. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 91 (2011), 1564–1571.
15. 15 Asai, H., Hirata, J., Hirano, A., et al. Activation of aryl hydrocarbon receptor mediates suppression of hypoxia inducible factor-dependent erythropoietin expression by indoxyl sulfate. Am J Physiol Cell Physiol 310 (2016), C142–C150.
16. 16 Jacobi, J., Porst, M., Cordasic, N., et al. Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. Kidney Int 69 (2006), 2013–2021.
17. 17 Futrakul, N., Butthep, P., Laohareungpanya, N., et al. A defective angiogenesis in chronic kidney disease. Ren Fail 30 (2008), 215–217.
18. 18 Kido, M., Du, L., Sullivan, C.C., et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 46 (2005), 2116–2124.
19. 19 Patel, T.H., Kimura, H., Weiss, C.R., et al. Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 68 (2005), 144–154.
20. 20 Pajusola, K., Kunnapuu, J., Vuorikoski, S., et al. Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 19 (2005), 1365–1367.
21. 21 Holdstock, L., Meadowcroft, A.M., Maier, R., et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 27 (2016), 1234–1244.
22. 22 Besarab, A., Chernyavskaya, E., Motylev, I., et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 27 (2016), 1225–1233.
23. 23 Bernhardt, W.M., Wiesener, M.S., Scigalla, P., et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21 (2010), 2151–2156.
24. 24 Maxwell, P.H., Eckardt, K.U., HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Na Rev Nephrol 12 (2016), 157–168.
25. 25 Nangaku, M., Izuhara, Y., Takizawa, S., et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 27 (2007), 2548–2554.
26. 26 Warnecke, C., Griethe, W., Weidemann, A., et al. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 17 (2003), 1186–1188.
27. 27 Vogler, M., Zieseniss, A., Hesse, A.R., et al. Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult. Pflugers Arch 467 (2015), 2141–2149.
28. 28 Aragones, J., Schneider, M., Van Geyte, K., et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 40 (2008), 170–180.
29. 29 Schley, G., Klanke, B., Schodel, J., et al. Selective stabilization of HIF-1alpha in renal tubular cells by 2-oxoglutarate analogues. Amer J Pathol 181 (2012), 1595–1606.
30. 30 Paoni, N.F., Peale, F., Wang, F., et al. Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice. Physiol Genomics 11 (2002), 263–272.
31. 31 Lee, C.W., Stabile, E., Kinnaird, T., et al. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. J Amer Coll Cardiol 43 (2004), 474–482.
32. 32 Heffelfinger, S.C., Hawkins, H.H., Barrish, J., et al. SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol 28A (1992), 136–142.
33. 33 Martens, L.K., Kirschner, K.M., Warnecke, C., et al. Hypoxia-inducible factor-1 (HIF-1) is a transcriptional activator of the TrkB neurotrophin receptor gene. J Biol Chem 282 (2007), 14379–14388.
34. 34 Li, S., Crooks, P.A., Wei, X., et al. Toxicity of dipyridyl compounds and related compounds. Crit Rev Toxicol 34 (2004), 447–460.
35. 35 Amann, K., Neimeier, K.A., Schwarz, U., et al. Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle. Am J Kidney Dis 30 (1997), 382–388.
36. 36 Flisinski, M., Brymora, A., Elminowska-Wenda, G., et al. Influence of different stages of experimental chronic kidney disease on rats locomotor and postural skeletal muscles microcirculation. Ren Fail 30 (2008), 443–451.
37. 37 Fleck, C., Appenroth, D., Jonas, P., et al. Suitability of 5/6 nephrectomy (5/6NX) for the induction of interstitial renal fibrosis in rats–influence of sex, strain, and surgical procedure. Exp Toxicol Pathol 57 (2006), 195–205.
38. 38 Milkiewicz, M., Pugh, C.W., Egginton, S., Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J Physiol 560 (2004), 21–26.
39. 39 Shyu, K.G., Wang, M.T., Wang, B.W., et al. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 54 (2002), 576–583.
40. 40 Vincent, K.A., Shyu, K.G., Luo, Y., et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 102 (2000), 2255–2261.
41. 41 Tuomisto, T.T., Rissanen, T.T., Vajanto, I., et al. HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 174 (2004), 111–120.
42. 42 Jurgensen, J.S., Rosenberger, C., Wiesener, M.S., et al. Persistent induction of HIF-1alpha and -2alpha in cardiomyocytes and stromal cells of ischemic myocardium. FASEB J 18 (2004), 1415–1417.
43. 43 Philipp, S., Jurgensen, J.S., Fielitz, J., et al. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail 8 (2006), 347–354.
44. 44 Lijkwan, M.A., Hellingman, A.A., Bos, E.J., et al. Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia. Hum Gene Ther 25 (2014), 41–49.
45. 45 Loinard, C., Ginouves, A., Vilar, J., et al. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 120 (2009), 50–59.
46. 46 Wang, Z., Schley, G., Turkoglu, G., et al. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant 27 (2012), 929–936.
47. 47 Song, Y.R., You, S.J., Lee, Y.M., et al. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant 25 (2010), 77–85.
48. 48 Tanaka, T., Kojima, I., Ohse, T., et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 85 (2005), 1292–1307.
49. 49 Yu, X., Fang, Y., Liu, H., et al. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant 27 (2012), 3110–3119.
50. 50 Provenzano, R., Fadda, G., Bernardo, M., et al. FG-2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD. AJKD, 51, 2008, B80.
51. 51 Harper, S.J., Downs, L., Tomson, C.R., et al. Elevated plasma vascular endothelial growth factor levels in non-diabetic predialysis uraemia. Nephron 90 (2002), 341–343.
52. 52 Tan, J.T., Prosser, H.C., Vanags, L.Z., et al. High-density lipoproteins augment hypoxia-induced angiogenesis via regulation of post-translational modulation of hypoxia-inducible factor 1alpha. FASEB J 28 (2014), 206–217.
53. 53 Jeon, H., Kim, H., Choi, D., et al. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol 71 (2007), 1676–1684.
54. 54 Krenning, G., Dankers, P.Y., Drouven, J.W., et al. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol 296 (2009), F1314–F1322.
55. 55 Akita, T., Murohara, T., Ikeda, H., et al. Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization. Lab Invest 83 (2003), 65–73.
56. 56 Jie, K.E., Zaikova, M.A., Bergevoet, M.W., et al. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. Nephrol Dial Transplant 25 (2010), 1875–1882.
57. 57 Yamaguchi, J., Tanaka, T., Eto, N., et al. Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein delta. Kidney Int 88 (2015), 262–275.
58. 58 Ito, W.D., Arras, M., Winkler, B., et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 80 (1997), 829–837.
59. 59 Hams, E., Saunders, S.P., Cummins, E.P., et al. The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells. Shock 36 (2011), 295–302.
60. 60 Hart, M.L., Grenz, A., Gorzolla, I.C., et al. Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor. J Immunol 186 (2011), 4367–4374.
61. 61 Takeda, Y., Costa, S., Delamarre, E., et al. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 479 (2011), 122–126.
62. 62 Olson, E., Demopoulos, L., Haws, T.F., et al. Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vasc Med 19 (2014), 473–482.
63. 63 Schley, G., Scholz, H., Kraus, A., et al. Hypoxia inhibits nephrogenesis through paracrine Vegfa despite the ability to enhance tubulogenesis. Kidney Int 88 (2015), 1283–1292.